Related Experiment Video
Updated: May 11, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Procedural and Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous
Domenico Simone Castiello1, Federica Buongiorno1, Lina Manzi1
1Department of Advanced Biomedical Sciences, University of Naples Federico II, 80138 Naples, Italy.
Insights
Patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) face high bleeding risks. This review explores strategies to balance antithrombotic therapy for optimal outcomes in this complex patient group.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- Percutaneous coronary intervention (PCI) is a primary treatment for coronary artery disease (CAD).
- Dual antiplatelet therapy (DAPT) is crucial post-PCI, but many patients also require oral anticoagulants (OACs) for atrial fibrillation (AF).
- Combining OACs with DAPT significantly elevates bleeding risk.
Purpose of the Study:
- To review current procedural and antithrombotic strategies for patients with AF undergoing PCI.
- To optimize the balance between preventing ischemic events and minimizing bleeding complications in this population.
Main Methods:
- Review of existing literature on antithrombotic strategies in patients with AF undergoing PCI.
- Comparison of dual antithrombotic therapy (DAT) versus triple antithrombotic therapy (TAT) regarding bleeding and thrombotic risks.
- Discussion of procedural considerations to mitigate risks.
Main Results:
- Dual antithrombotic therapy (DAT) reduces bleeding compared to triple antithrombotic therapy (TAT).
- However, DAT may be associated with an increased risk of stent thrombosis.
- Patients with AF undergoing PCI present unique challenges requiring tailored management.
Conclusions:
- Managing antithrombotic therapy in AF patients undergoing PCI requires careful consideration of individual risk factors.
- Strategies to reduce bleeding complications are essential.
- Further research and optimized protocols are needed to improve both ischemic and bleeding outcomes.
Abstract:
In the past decades, percutaneous coronary intervention (PCI) has become the most common modality for myocardial revascularization in patients with coronary artery disease (CAD). Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is essential in all patients undergoing PCI to prevent thrombotic complications. A large proportion of patients undergoing PCI also have concomitant atrial fibrillation (AF), thus requiring an oral anticoagulant (OAC) to prevent ischemic stroke or systemic embolism. However, the association between OAC and DAPT further increases the risk of bleeding. Compared with a triple antithrombotic therapy (TAT), dual antithrombotic therapy (DAT) has shown to reduce bleeding events, but at the cost of higher risk of stent thrombosis. In this field, patients with AF undergoing PCI represent a special population with significant challenges, and several strategies are needed to reduce the risk for bleeding complications. In this review, we will discuss both the procedural and antithrombotic strategies to optimize ischemic and bleeding outcomes in patients with AF undergoing PCI.
Related Concept Videos
Cardiac Catheterization I: Pre-Procedure Overview
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Angina IV: Management
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis III: Interprofessional Care

